Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration. by Denis Mustafov (19137870)

“…Microscopic images of colonies were taken at ×40 magnification. The data represents mean values and standard deviation, n = 3. <b>Legends:</b> ns: non-significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.…”

CKO mice display decreased skin barrier function and perturbed homeostasis. by Kevin J. Mills (9270966)

Subjects:

Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

“…Microscopic images were captured at ×40 magnification. Data represent mean values ± standard deviation, n = 3. <b>Legends:</b> ns: non-significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.…”

Decreased expression of tight junction proteins and disruption of intestinal barrier integrity in DSS-induced colitis mouse model. by Mariam Wed Eladham (21439745)

Elevated concentrations of serum MMA among participants with decreased cognitive performance. by Yige Liu (11940344)

BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. by Luqiong Liu (11537092)

Madrasin decreases transcription of protein-coding genes. by Michael Tellier (8284752)

Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

“…The values are expressed as the means ± SDs and were analyzed according to the variance of the factorial design. **, *** and ****denote <i>p</i> < 0.01, < 0.001 and < 0.0001, respectively; ns  =  not significant.…”

Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. by Luqiong Liu (11537092)

Most significant muscle activation values. by María Benito-de-Pedro (22057468)

Subjects:

Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Significant repeated measurements sEMG outcomes. by María Benito-de-Pedro (22057468)

Subjects:

Significant single measurement sEMG outcomes. by María Benito-de-Pedro (22057468)

Subjects:

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of optical coherence tomography and fundus findings in a representative non-recurrent eye. by Yasuyuki Sotani (20114144)

Subjects:

Mean interval from initial diagnosis to initiation of non-pharmacological treatment by year. by Mingee Choi (15250732)

Subjects:

Lipidomic analysis of epidermis using LC-IMS-CID-MS reveals major changes in CKO// epidermis. by Kevin J. Mills (9270966)

Subjects: